Metachronous Brain Tumor in 177Lu-PSMA Scan in a Patient with Metastatic Castration Resistant Prostate Cancer Mimicking Disease Progression.

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Radionuclide Therapy Pub Date : 2023-02-23 DOI:10.4274/mirt.galenos.2021.55376

Elahe Pirayesh, Mehrdad Tavakoli

引用次数: 0

Abstract

A 66-year old man known case of metastatic castration resistant prostate cancer underwent successful 6 cycles treatment with 177Lu- prostate-specific membrane antigen. On the last post therapy whole body scan a new lesion in the skull was noted, suspected for disease progression. One week later, the patient complained from weakness of left upper extremity and brain magnetic resonance imaging revealed a brain tumor, confirmed as glioblastoma pathologically.

Abstract Image

查看原文本刊更多论文

模拟疾病进展的转移性去势抵抗性前列腺癌患者的177Lu-PSMA扫描显示异时性脑肿瘤

一例66岁男性转移性去势抵抗性前列腺癌患者，经177Lu-前列腺特异性膜抗原治疗6个周期成功。在治疗后的最后一次全身扫描中，发现颅骨有新的病变，怀疑疾病进展。一周后患者主诉左上肢无力，脑磁共振示脑肿瘤，病理证实为胶质母细胞瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Radionuclide Therapy RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.